Navigation Links
Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer
Date:12/14/2007

rican, California, and San Diego bar associations.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 18 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

This press release includes forward-looking statements regarding Isis Pharmaceuticals and the Company's business. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward- looking stateme
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... York (PRWEB) July 12, 2014 ... for various reagents used in the life ... driving the life science reagents market towards ... include manufacturers and providers of life science ... Market Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , The ...
(Date:7/11/2014)... 2014 BCC Research ( http://www.bccresearch.com ) ... CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS , the global ... nearly $140 billion in 2013. This is estimated to ... compound annual growth rate (CAGR) of 28.6%. , New ... and exciting possibilities within the broader PCR field. The ...
(Date:7/11/2014)... 11, 2014 Cayenne Medical, Inc., ... in the soft tissue reconstruction segment, announced the ... for surgeries involving the shoulder and extremities. The ... novel, inserter-controlled deployment method. The unique delivery eliminates ... anchor pull-out, or anchor displacement (also commonly know ...
(Date:7/10/2014)... July 10, 2014 Understanding the need ... cell lines, and the gap that currently exists in ... expand its industry-leading portfolio of validated ion channel and ... channel-expressing cell lines, as ion channels control many critical ... this activity creates the potential to treat a variety ...
Breaking Biology Technology:Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3
... WILMINGTON, N.C., Sept. 9 Wilmington Pharmaceuticals announced ... granted marketing approval for METOZOLV((TM)) ODT (metoclopramide HCl), an ... gastroesophageal reflux disease (GERD) and diabetic gastroparesis. Wilmington has ... pharmaceutical company with a focus on gastrointestinal disorders. , ...
... , SAN DIEGO, Sept. 9 Orexigen((R) )Therapeutics, Inc. ... obesity, today announced that the Company will be speaking at two upcoming investor ... , Morgan Stanley Global Healthcare Unplugged Conference, ... Time, Location: Grand Hyatt Hotel, New York, ...
... , , , , ... SAN FRANCISCO, Sept. 9 Medivation, Inc. (Nasdaq: MDVN ) ... the following conferences: , , , The ... Eastern Time at the Millennium Broadway Hotel in New York , ...
Cached Biology Technology:Wilmington Pharmaceuticals Receives FDA Approval for Orally Disintegrating Metoclopramide Tablet 2Wilmington Pharmaceuticals Receives FDA Approval for Orally Disintegrating Metoclopramide Tablet 3Wilmington Pharmaceuticals Receives FDA Approval for Orally Disintegrating Metoclopramide Tablet 4Medivation Announces Participation in Upcoming Conferences 2
(Date:7/11/2014)... new report from the Wildlife Conservation Society shows ... help economically valuable species such as lobster, conch, ... help re-colonize nearby reef areas. , The reporttitled ... systematic review of research literature from no-take areas ... Dr. Craig Dahlgren, a recognized expert in marine ...
(Date:7/11/2014)... July 11, 2014--Researchers at the Department of Energy,s ... 100 awards, presented by R&D Magazine in recognition ... "These awards recognize the tremendous value of our ... "Research and development at the National Labs continues ... and pursue the scientific and technological innovations necessary ...
(Date:7/11/2014)... many fires burning in eastern New South Wales, Australia ... , At 03:35 UTC on July 11 (12:35 p.m. ... passed over eastern New South Wales (NSW), the Moderate ... image of the region and spotted smoke (light brown) ... thermal bands, are outlined in red. , The New ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... In Nature, cells and tissues assemble and organize themselves ... their structure and function, such as the elasticity of ... design principles have now been successfully replicated in the ... Inspired Engineering and the School of Engineering and Applied ...
... ANN ARBOR, Mich. Why do some diseases ... the University of Michigan have found neural tissue contains ... susceptibility to a debilitating childhood movement disorder. ... and repetitive movements or abnormal postures. It,s caused by ...
... is an imposing bull always in search of the best ... 4 metres in length belongs to a group of 14 ... scientific assistants since recently. At the beginning of the Antarctic ... the mighty elephant seal bulls were tagged with state-of-the-art satellite ...
Cached Biology News:Harvard's Wyss Institute uses nature's design principles to create specialized nanofabrics 2Harvard's Wyss Institute uses nature's design principles to create specialized nanofabrics 3Neural tissue contains imbalanced levels of proteins, U-M study finds 2Seal bulls in the service of science 2Seal bulls in the service of science 3